We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+80.92%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$2.1B
AUM Growth
+$644M
Cap. Flow
-$42.2M
Cap. Flow %
-2.01%
Top 10 Hldgs %
63.64%
Holding
44
New
8
Increased
15
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$35.4M
2
ENGN icon
enGene Therapeutics
ENGN
+$31.4M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$28.9M
4
KALV
KalVista Pharmaceuticals
KALV
+$28.8M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$25.4M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$251M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$29.5M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$22.8M
4
CABA icon
Cabaletta Bio
CABA
+$21.5M
5
SVRA icon
Savara
SVRA
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.1B
$564M 26.85%
8,493,321
– –
FDMT icon
2
4D Molecular Therapeutics
FDMT
$532M
$140M 6.67%
4,400,000
+975,969
+29% +$24.9M
OCUL icon
3
Ocular Therapeutix
OCUL
$1.79B
$116M 5.52%
12,762,462
+4,986,702
+64% +$35.4M
SYRE icon
4
Spyre Therapeutics
SYRE
$8.54B
$82.4M 3.92%
2,171,782
-200,932
-8% -$5.82M
MRUS
5
DELISTED
Merus
MRUS
$80.6M 3.83%
1,790,214
-358,000
-17% -$14.5M
PHVS icon
6
Pharvaris
PHVS
$2.28B
$78.5M 3.73%
3,395,606
– –
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$74.1M 3.53%
6,249,731
+2,157,000
+53% +$28.8M
ELVN icon
8
Enliven Therapeutics
ELVN
$3.92B
$70.8M 3.37%
4,026,331
+1,071,429
+36% +$16.4M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.09B
$68M 3.23%
3,882,671
+48
+0% +$931
DNTH icon
10
Dianthus Therapeutics
DNTH
$5.84B
$62.8M 2.99%
2,094,373
+1,166,667
+126% +$25.4M
DYN icon
11
Dyne Therapeutics
DYN
$4.7B
$61.7M 2.94%
2,173,913
– –
APLT
12
DELISTED
Applied Therapeutics
APLT
$61.7M 2.94%
9,075,000
+2,825,000
+45% +$12.7M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.15B
$60.4M 2.87%
4,394,527
+1,966,142
+81% +$23.4M
ATXS
14
DELISTED
Astria Therapeutics
ATXS
$50.8M 2.42%
3,608,645
+382,839
+12% +$4.77M
MRSN
15
DELISTED
Mersana Therapeutics
MRSN
$50.7M 2.41%
453,120
– –
ENGN icon
16
enGene Therapeutics
ENGN
$120M
$43.5M 2.07%
+2,565,841
New +$31.4M
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.58B
$43.1M 2.05%
706,126
+352,500
+100% +$15.8M
HLVX
18
DELISTED
HilleVax
HLVX
$34.5M 1.64%
2,075,000
– –
COGT icon
19
Cogent Biosciences
COGT
$6.65B
$34.5M 1.64%
5,129,167
+445,000
+10% +$2.75M
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.13B
$33.2M 1.58%
+1,818,182
New +$28.9M
CABA icon
21
Cabaletta Bio
CABA
$437M
$26.7M 1.27%
1,563,952
-1,000,000
-39% -$21.5M
ARVN icon
22
Arvinas
ARVN
$518M
$25.9M 1.23%
627,788
– –
TSHA icon
23
Taysha Gene Therapies
TSHA
$1.68B
$25.8M 1.23%
9,000,000
-1,412,872
-14% -$2.94M
AQST icon
24
Aquestive Therapeutics
AQST
$463M
$23.7M 1.13%
+5,555,555
New +$18.5M
TERN
25
DELISTED
Terns Pharmaceuticals
TERN
$22.4M 1.06%
3,410,058
-1,087,059
-24% -$7.1M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2024 Portfolio in Review

As of Q1 2024, VR Adviser held 44 positions worth $2.1B, up 44% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

VR Adviser's Q1 2024 filing shows 8 new, 15 increased, 6 reduced and 6 closed positions. Its largest new stake was enGene Therapeutics: 2,565,841 shares worth $43.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $251M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • VR Adviser's largest Q1 2024 buy was enGene Therapeutics: 2,565,841 shares worth $43.5M.
  • VR Adviser added most to Ocular Therapeutix in Q1 2024, an estimated $35.4M increase.
  • VR Adviser's biggest Q1 2024 reduction was Cabaletta Bio, cutting an estimated $21.5M.
  • VR Adviser fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $251M.
  • VR Adviser's ten largest holdings make up 64% of its $2.1B portfolio in Q1 2024.
  • VR Adviser opened 8 new positions and closed 6 in Q1 2024.
  • VR Adviser's portfolio value rose 44% quarter-over-quarter to $2.1B.

Based on VR Adviser's 13F filing for Q1 2024, filed 15 May 2024.